Journal
FEMS MICROBIOLOGY LETTERS
Volume 358, Issue 2, Pages 170-179Publisher
WILEY-BLACKWELL
DOI: 10.1111/1574-6968.12525
Keywords
TB; vaccine; tuberculosis; mucosal vaccine
Categories
Funding
- SWAN Alliance (South-West Alliance Network, of Royal Holloway, St Georges and Kingston University)
- EU grant (Innovac) [LSH-2005-036871]
- Dunhill Medical Trust
- CASE PhD. studentship from the BBSRC
- Boehringer Ingelheim
Ask authors/readers for more resources
Recombinant Bacillus subtilis spores expressing a TB antigen, MPT64, were tested for their ability to protect mice against tuberculosis challenge. A chimeric gene consisting of the spore coat gene cotB fused to mpt64 was constructed, and expression of a stable CotB-MPT64 hybrid protein of the spore coat verified. Spores were evaluated as a live vaccine and also formaldehyde inactivated. Mice were given three doses of spores or alternatively used in a prime-boost regimen with BCG. The results showed that inactivated recombinant spores were able to reduce the bacterial burden in the lungs of mice to comparable levels to that of BCG. In the prime-boost regimen, both live and inactivated spores showed a reduction in bacterial load in comparison with BCG. ELISPOT and polyfunctional T-cell analysis were performed to examine cellular responses and showed that antigen-specific secretion of Th1 cytokines was stimulated after immunisation with inactive recombinant spores and BCG. In summary, recombinant spores can elicit Th1 responses, which are important for protection against TB disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available